Clinical Trial

Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 12, 2024 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the objective response rate, disease control rate, progression-free survival, overall survival, surgical conversion rate and safety of irinotecan liposome combined with 5-FU/LV+ bevacizumab regimen in first-line treatment of advanced metastatic colorectal cancer patients.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-03-26; most recent amendment 2024-08-08.
Status change: Not Yet Recruiting → Recruiting 2024-08-08
Trial Details
NCT Number NCT06341296
Lead Sponsor West China Hospital
Conditions Metastatic Colorectal Cancer
Enrollment 86 participants
Start Date 2024-06-30
Primary Completion 2026-04 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2024-08-12